Our detailed meta-analysis of adverse events associated with IDH inhibitors showed that all grades of adverse events commonly (> 15%) occur in IDH-mutated AML patients treated with IDH inhibitors are nausea (30%), blood bilirubin increased (24%), diarrhea (24%), constipation (23%), vomiting (21%), thrombocytopenia(20%), neutropenia(18%), anemia (17%) and decreased appetite (17%), most of which are gastrointestinal adverse events. Here, IDH2 is linked to acute myeloid leukemia.